Monthly Prescribing Reference

Nasal Spray Formulation of Bumetanide Under FDA Review

A Prescription Drug User Fee Act target date of September 14, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) ...
AOL

FDA approves Neffy, a nasal spray alternative to an EpiPen that does not need a needle to stop an allergic reaction

Aug. 26—Those at risk of a severe allergic reaction always have handy an EpiPen just in case. But soon their life might be saved by a spray in the nose rather than a needle to the thigh. Last week the ...

Aptar’s Intranasal Delivery System Used in Phase II Clinical Study for Investigational SPONTAN® Nasal Spray

Aptar Pharma’s Intranasal Delivery System Used in Phase II Clinical Study Investigational SPONTAN® Nasal Spray ...

SCIENTURE Broadens Commercial Access for REZENOPY(TM), Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions

As previously disclosed, Scienture, LLC, a wholly-owned subsidiary of Scienture Holdings, Inc., entered into a definitive agreement with Summit Biosciences Inc. (a Kindeva subsidiary) in March 2025, ...

Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session

Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that a moderated ...
Medscape

FDA OKs Esketamine Nasal Spray Monotherapy for Resistant Depression

The US Food and Drug Administration (FDA) has approved a supplemental new drug application allowing esketamine nasal spray (Spravato; Johnson & Johnson) to be used as a standalone treatment in adults ...
AOL

FDA-approved nasal spray for severe depression can lead to remission

The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images. Hundreds of millions of ...
Yahoo

FDA approves Spravato, first monotherapy nasal spray to treat depression

Add Yahoo as a preferred source to see more of our stories on Google. Johnson & Johnson’s Spravato nasal spray has been approved to treat a major depressive disorder in adults who have had an ...
WTEN

FDA approves first nasal spray to treat dangerous allergic reactions

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. U.S. health officials on Friday approved a ...
KSAT

FDA approves first nasal spray for major depression disorder

FILE - Food and Drug Administration (FDA) building is shown in Silver Spring, Md., Dec. 10, 2020. (AP Photo/Manuel Balce Ceneta, File) (Manuel Balce Ceneta, Copyright ...
Houston Public Media

FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)

The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now cleared for use as a standalone treatment for depression. Spravato is made ...
Yahoo

FDA approves Spravato, first monotherapy nasal spray to treat depression

Johnson & Johnson’s Spravato nasal spray has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced ...